Gao Fei, Sabbineni Harika, Artham Sandeep, Somanath Payaningal R
Clinical and Experimental Therapeutics, University of Georgia and Charlie Norwood VA Medical Center, Augusta, Georgia.
Department of Urology, The First Affiliated Hospital of Chongqing University, Chongqing, China.
J Cell Physiol. 2017 Oct;232(10):2599-2609. doi: 10.1002/jcp.25791. Epub 2017 Feb 9.
Although numerous studies have implicated Akt and Src kinases in vascular endothelial growth factor (VEGF) and Angiopoietin-1 (Ang-1)-induced endothelial-barrier regulation, a link between these two pathways has never been demonstrated. We determined the long-term effects of Akt inhibition on Src activity and vice versa, and in turn, on the human microvascular endothelial cell (HMEC) barrier integrity at the basal level, and in response to growth factors. Our data showed that Akt1 gene knockdown increases gap formation in HMEC monolayer at the basal level. Pharmacological inhibition of Akt, but not Src resulted in exacerbated VEGF-induced vascular leakage and impaired Ang-1-induced HMEC-barrier protection in vitro at 24 hr. Whereas inhibition of Akt had no effect on VEGF-induced HMEC gap formation in the short term, inhibition of Src blunted this process. In contrast, inhibition of Akt disrupted the VEGF and Ang-1 stabilized barrier integrity in the long-term while inhibition of Src did not. Interestingly, both long-term Akt inhibition and Akt1 gene knockdown in HMECs resulted in increased Tyr416 phosphorylation of Src. Treatment of HMECs with transforming growth factor-β1 (TGFβ1) that inhibited Akt Ser473 phosphorylation in the long-term, activated Src through increased Tyr416 phosphorylation and decreased HMEC-barrier resistance. The effect of TGFβ1 on endothelial-barrier breakdown was blunted in Akt1 deficient HMEC monolayers, where endothelial-barrier resistance was already impaired compared to the control. To our knowledge, this is the first report demonstrating a direct cross-talk between Akt and Src in endothelial-barrier regulation.
尽管众多研究表明Akt和Src激酶参与血管内皮生长因子(VEGF)和血管生成素-1(Ang-1)诱导的内皮屏障调节,但这两条途径之间的联系从未得到证实。我们确定了抑制Akt对Src活性的长期影响,反之亦然,进而确定其对基础水平以及对生长因子应答时人微血管内皮细胞(HMEC)屏障完整性的影响。我们的数据表明,敲低Akt1基因会增加基础水平下HMEC单层中的间隙形成。对Akt进行药理学抑制而非Src,会在24小时时加剧VEGF诱导的血管渗漏,并损害Ang-1诱导的体外HMEC屏障保护作用。虽然抑制Akt在短期内对VEGF诱导的HMEC间隙形成没有影响,但抑制Src会减弱这一过程。相反,长期抑制Akt会破坏VEGF和Ang-1稳定的屏障完整性,而抑制Src则不会。有趣的是,长期抑制Akt以及敲低HMECs中的Akt1基因均会导致Src的Tyr416磷酸化增加。用转化生长因子-β1(TGFβ1)处理HMECs,长期抑制Akt的Ser473磷酸化,通过增加Tyr416磷酸化激活Src并降低HMEC屏障抗性。在Akt1缺陷的HMEC单层中,TGFβ1对内皮屏障破坏的作用减弱,与对照相比,其内皮屏障抗性已经受损。据我们所知,这是第一份证明Akt和Src在内皮屏障调节中存在直接相互作用的报告。